These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 29034113)

  • 1. Low Neurotoxicity of ONX-0914 Supports the Idea of Specific Immunoproteasome Inhibition as a Side-Effect-Limiting, Therapeutic Strategy.
    von Brzezinski L; Säring P; Landgraf P; Cammann C; Seifert U; Dieterich DC
    Eur J Microbiol Immunol (Bp); 2017 Sep; 7(3):234-245. PubMed ID: 29034113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors.
    Downey-Kopyscinski S; Daily EW; Gautier M; Bhatt A; Florea BI; Mitsiades CS; Richardson PG; Driessen C; Overkleeft HS; Kisselev AF
    Blood Adv; 2018 Oct; 2(19):2443-2451. PubMed ID: 30266819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibiting the immunoproteasome's β5i catalytic activity affects human peripheral blood-derived immune cell viability.
    Pletinckx K; Vaßen S; Schlusche I; Nordhoff S; Bahrenberg G; Dunkern TR
    Pharmacol Res Perspect; 2019 Aug; 7(4):e00482. PubMed ID: 31236277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma.
    Ettari R; Zappalà M; Grasso S; Musolino C; Innao V; Allegra A
    Pharmacol Ther; 2018 Feb; 182():176-192. PubMed ID: 28911826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ONX 0914 Lacks Selectivity for the Cardiac Immunoproteasome in CoxsackievirusB3 Myocarditis of NMRI Mice and Promotes Virus-Mediated Tissue Damage.
    Neumaier HL; Harel S; Klingel K; Kaya Z; Heuser A; Kespohl M; Beling A
    Cells; 2020 Apr; 9(5):. PubMed ID: 32354159
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunoproteasome Activity and Content Determine Hematopoietic Cell Sensitivity to ONX-0914 and to the Infection of Cells with Lentiviruses.
    Vagapova E; Burov A; Spasskaya D; Lebedev T; Astakhova T; Spirin P; Prassolov V; Karpov V; Morozov A
    Cells; 2021 May; 10(5):. PubMed ID: 34066177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoproteasome subunit LMP7 deficiency and inhibition suppresses Th1 and Th17 but enhances regulatory T cell differentiation.
    Kalim KW; Basler M; Kirk CJ; Groettrup M
    J Immunol; 2012 Oct; 189(8):4182-93. PubMed ID: 22984077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoproteasome inhibition prevents chronic antibody-mediated allograft rejection in renal transplantation.
    Li J; Basler M; Alvarez G; Brunner T; Kirk CJ; Groettrup M
    Kidney Int; 2018 Mar; 93(3):670-680. PubMed ID: 29229189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoproteasome Inhibition Impairs T and B Cell Activation by Restraining ERK Signaling and Proteostasis.
    Schmidt C; Berger T; Groettrup M; Basler M
    Front Immunol; 2018; 9():2386. PubMed ID: 30416500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No prolongation of skin allograft survival by immunoproteasome inhibition in mice.
    Mundt S; Basler M; Sawitzki B; Groettrup M
    Mol Immunol; 2017 Aug; 88():32-37. PubMed ID: 28582644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different roles of bortezomib and ONX 0914 in acute kidney injury.
    Zhang XZ; Han F; Ding CG; Dou M; Wang YX; Xue WJ; Ding XM; Zheng J; Xu CX; Tian PX
    Int Immunopharmacol; 2020 Mar; 82():106259. PubMed ID: 32143000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative analysis between proteasome and immunoproteasome inhibition in cellular and humoral alloimmunity.
    Eleftheriadis T; Pissas G; Antoniadi G; Liakopoulos V; Stefanidis I
    Int Immunopharmacol; 2017 Sep; 50():48-54. PubMed ID: 28628770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the Immunoproteasome Subunit LMP7 with ONX 0914 Ameliorates Graft-versus-Host Disease in an MHC-Matched Minor Histocompatibility Antigen-Disparate Murine Model.
    Zilberberg J; Matos J; Dziopa E; Dziopa L; Yang Z; Kirk CJ; Assefnia S; Korngold R
    Biol Blood Marrow Transplant; 2015 Sep; 21(9):1555-64. PubMed ID: 26093043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurotoxicity induced by antineoplastic proteasome inhibitors.
    Alé A; Bruna J; Navarro X; Udina E
    Neurotoxicology; 2014 Jul; 43():28-35. PubMed ID: 24525285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition and deficiency of the immunoproteasome subunit LMP7 suppress the development and progression of colorectal carcinoma in mice.
    Koerner J; Brunner T; Groettrup M
    Oncotarget; 2017 Aug; 8(31):50873-50888. PubMed ID: 28881611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoproteasome inhibition attenuates experimental psoriasis.
    Del Rio Oliva M; Mellett M; Basler M
    Front Immunol; 2022; 13():1075615. PubMed ID: 36591277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteasome or immunoproteasome inhibitors cause apoptosis in human renal tubular epithelial cells under normoxic and hypoxic conditions.
    Eleftheriadis T; Pissas G; Antoniadi G; Liakopoulos V; Stefanidis I
    Int Urol Nephrol; 2016 Jun; 48(6):907-15. PubMed ID: 26920131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoproteasome-Selective Inhibitors: A Promising Strategy to Treat Hematologic Malignancies, Autoimmune and Inflammatory Diseases.
    Ettari R; Previti S; Bitto A; Grasso S; Zappalà M
    Curr Med Chem; 2016; 23(12):1217-38. PubMed ID: 26965184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-leukemic activity and mechanisms underlying resistance to the novel immunoproteasome inhibitor PR-924.
    Niewerth D; van Meerloo J; Jansen G; Assaraf YG; Hendrickx TC; Kirk CJ; Anderl JL; Zweegman S; Kaspers GJ; Cloos J
    Biochem Pharmacol; 2014 May; 89(1):43-51. PubMed ID: 24552657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis.
    Schmidt N; Gonzalez E; Visekruna A; Kühl AA; Loddenkemper C; Mollenkopf H; Kaufmann SH; Steinhoff U; Joeris T
    Gut; 2010 Jul; 59(7):896-906. PubMed ID: 20581238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.